CLICK HERE TO LEARN MORE OR REGISTER | Live Webinar + On-Demand Course Access
Biotech and Pharmaceutical Patent Law: Cutting-Edge Issues to Watch For
Webinar Date: Friday, September 16, 2022, from 12:00 pm to 1:30 pm (ET)
Several court cases continue to shape the biotech and pharmaceutical patent litigation in the United States and Canada.
In the United States, Amgen Inc. v. Sanofi-Aventis (2021) has revived the discussion on the enablement of genus claims in biotechnology inventions. Moreover, the multiple filings for abbreviated new drug applications (ANDA) also raise concerns, particularly in cases that may provoke multidistrict litigation. These and other developments further expand the patent litigation landscape, introducing new regulations that practitioners must be aware of to avoid legal pitfalls.
In Canada, summary trials are increasingly affecting the way litigation is proceeding. Issues concerning cases that impact the scope of the Notice of Allegation, certificates of supplementary protection, and the Patent Medicines Price Review Board, as well as those relating to claim construction, obviousness, and patentable subject matter, must be considered.
Join a panel of key thought leaders and distinguished professionals organized by The Knowledge Group as they provide a comprehensive discussion of the recent litigation trends in the biotech and pharmaceutical industry. Speakers, among other things, will also offer practical tips and strategies in this ever-changing regulatory landscape.
Some of the major topics that will be covered in this course are:
- Recent Litigation Trends and Developments in the Biotech and Pharmaceutical Industry
- Enablement of Genus Claims for Biotechnology Inventions
- Multiple Filing of Abbreviated New Drug Applications (ANDA): Implications
- Recent and Notable Court Cases
- What Lies Ahead